UK Regulator Approves MYQORZO, NICE Backs Reimbursement for Heart Drug
CYTK has more than doubled off its 52-week low of $32.89.
Summary
Cytokinetics secured UK marketing authorization for MYQORZO (aficamten) in symptomatic obstructive HCM, paired with NICE guidance recommending its use in England and Wales. This opens a major European market and triggers a commercial milestone payment. The concurrent MHRA and NICE decisions accelerate NHS access, expected later this year. The approval follows positive Phase 3 data and recent US launches, reinforcing aficamten's global commercial trajectory. With a ~$9.8B market cap, UK approval adds a meaningful revenue stream and validates the drug's regulatory profile ahead of other international submissions.
At the time of this announcement, CYTK was trading at $79.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $32.89 to $88.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.